

15 July 2016

ASX ANNOUNCEMENT

AUTOSTART BURETTE GRANTED US PATENT

Analytica (ASX:ALT) is pleased to announce that the AutoStart® burette system has been granted patent protection by the US Patent and Trademarks Office.

US Patent 9352080 has a priority date of 13 October 2005 and will expire on 17 Jan 2031, provided all renewal fees are paid.

CEO Geoff Daly said “Obtaining patent protection in the world’s largest medical device market is a major milestone and an important step in the commercialisation of the AutoStart infusion system. The patent process is lengthy and complex, with this national phase patent taking more than 10 years from the priority date. This patent is one of a number of AutoStart burette patents being pursued in the major medical device markets. Demonstrating that a product can achieve this level of intellectual property protection is valuable to licensees, and may encourage license deals from one of the larger infusion system manufacturers.”

The product is being sold under license in Australia and New Zealand by Medical Australia Ltd (ASX: MLA) under their Tuta FirstFlow® brand name.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the AutoStart System, visit: www.AutoStartBurette.com

For more information about Analytica, visit www.AnalyticaMedical.com

